Identification of Genomic Alterations Associated With Metastasis and Cancer Specific Survival in Clear Cell Renal Cell Carcinoma

被引:30
作者
Sanjmyatav, Jimsgene [1 ]
Junker, Kerstin
Matthes, Sophie
Muehr, Martin
Sava, Doriana
Sternal, Maria
Wessendorf, Sven
Kreuz, Markus
Gajda, Mieczyslaw
Wunderlich, Heiko
Schwaenen, Carsten
机构
[1] Jena Univ Hosp, Dept Urol, D-07740 Jena, Germany
关键词
kidney; carcinoma; renal cell; genetic markers; in situ hybridization; fluorescence; prognosis; GENETIC ALTERATIONS; HYBRIDIZATION; PROGRESSION; EXPRESSION; NUMBER; PREDICT; EVENTS; S100A4; TUMORS; GAIN;
D O I
10.1016/j.juro.2011.06.050
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We identified regions of DNA copy number changes that are significantly associated with metastasis and clinical outcome in patients with clear cell renal cell carcinoma. Materials and Methods: We analyzed 53 primary clear cell renal cell carcinomas, including 31 metastasized and 22 nonmetastasized tumors, by array comparative genomic hybridization with a median resolution of 1 to 1.5 Mbp. To validate copy number aberrations with potential prognostic value we performed fluorescence in situ hybridization analysis using commercially available fluorescent probes. Results: We identified 5 recurrent chromosomal aberrations that were significantly associated with metastasis, including gains of 1q21.3, 12q13.12, 12q13.3q14.1 and 20q11.21q13.2, and loss of 9p21.3p24.1. The most prominent of them with the highest OR for metastatic risk were loss of 9p21.3p24.1, and gains of 1q21.3 and 20q11.21q13.32. Eight alterations involving chromosomes 7, 9, 12, 16 and 20 significantly correlated with shortened cancer specific survival. The lowest p values on Kaplan-Meier analysis showed losses of 9p21.3p24.1 and 9q32q33.1, and gains of 7q36.3 and 20q11.21q13.32. Fluorescence in situ hybridization done in the same cohort for the 4 select regions 1q21.3, 7q36.3, 9p21.3p24.1 and 20q11.21q13.32 clearly confirmed the results of array comparative genomic hybridization. Conclusions: Data suggest that specific chromosomal alterations in clear cell renal cell carcinoma can be used to predict metastasis and cancer specific survival in patients with clear cell renal cell carcinoma. It seems possible to design a combined fluorescence in situ hybridization assay based on these genetic targets for outcome prediction, which can be used for routine diagnostics.
引用
收藏
页码:2078 / 2083
页数:6
相关论文
共 50 条
  • [41] The prognostic value of cancer stage-associated genes in clear cell renal cell carcinoma
    Ding, Xiao-Sheng
    Hua, Yi-Chun
    Han, Bing-Xuan
    An, Juan
    Zhou, Li-Li
    Xu, Wei -Ran
    Shi, Hui
    Zheng, Xi -Xi
    Shi, Wei -Wei
    Li, Xiao-Yan
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2023, 15 (08): : 5145 - 5158
  • [42] GALNT4 Predicts Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma
    Liu, Yidong
    Liu, Weisi
    Xu, Le
    Liu, Haiou
    Zhang, Weijuan
    Zhu, Yu
    Xu, Jiejie
    Gu, Jianxin
    JOURNAL OF UROLOGY, 2014, 192 (05) : 1534 - 1541
  • [43] Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
    Lee, Ji Won
    Park, Jeong Hwan
    Suh, Ja Hee
    Nam, Kyung Han
    Choe, Ji-Young
    Jung, Hae Yoen
    Chae, Ji Yoen
    Moon, Kyung Chul
    KOREAN JOURNAL OF PATHOLOGY, 2012, 46 (03) : 237 - 245
  • [44] Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma
    Ebru, Tastekin
    Fulya, Oz Puyan
    Hakan, Akdere
    Vuslat, Yurut-Caloglu
    Necdet, Sut
    Nuray, Can
    Filiz, Ozyilmaz
    INTERNATIONAL BRAZ J UROL, 2017, 43 (03): : 440 - 454
  • [45] Clear Cell Renal Cell Carcinoma With Borderline Features of Clear Cell Papillary Renal Cell Carcinoma Combined Morphologic, Immunohistochemical, and Cytogenetic Analysis
    Williamson, Sean R.
    Gupta, Nilesh S.
    Eble, John N.
    Rogers, Craig G.
    Michalowski, Susan
    Zhang, Shaobo
    Wang, Mingsheng
    Grignon, David J.
    Cheng, Liang
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (11) : 1502 - 1510
  • [46] Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma
    Li, Qinke
    Yang, Wenbo
    Lu, Maoqing
    Zhang, Ronggui
    MEDICAL SCIENCE MONITOR, 2020, 26
  • [47] Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
    Miao, Diana
    Margolis, Claire A.
    Gao, Wenhua
    Voss, Martin H.
    Li, Wei
    Martini, Dylan J.
    Norton, Craig
    Bosse, Dominick
    Wankowicz, Stephanie M.
    Cullen, Dana
    Horak, Christine
    Wind-Rotolo, Megan
    Tracy, Adam
    Giannakis, Marios
    Hodi, Frank Stephen
    Drake, Charles G.
    Ball, Mark W.
    Allaf, Mohamad E.
    Snyder, Alexandra
    Hellmann, Matthew D.
    Ho, Thai
    Motzer, Robert J.
    Signoretti, Sabina
    Kaelin, William G., Jr.
    Choueiri, Toni K.
    Van Allen, Eliezer M.
    SCIENCE, 2018, 359 (6377) : 801 - 805
  • [48] Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
    Bi, Mark
    Zhao, Siming
    Said, Jonathan W.
    Merino, Maria J.
    Adeniran, Adebowale J.
    Xie, Zuoquan
    Nawaf, Cayce B.
    Choi, Jaehyuk
    Belldegrun, Arie S.
    Pantuck, Allan J.
    Kluger, Harriet M.
    Bilguevar, Kaya
    Lifton, Richard P.
    Shuch, Brian
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (08) : 2170 - 2175
  • [49] In silico Study of Clinical Prognosis Associated MicroRNAs for Patients with Metastasis in Clear Cell Renal Carcinoma
    Wijaya, Ezra B.
    Mekala, Venugopala Reddy
    Zaenudin, Efendi
    Ng, Ka-Lok
    CURRENT BIOINFORMATICS, 2024, 19 (02) : 174 - 192
  • [50] A tumor-specific microRNA signature predicts survival in clear cell renal cell carcinoma
    Yu-Zheng Ge
    Ran Wu
    Hui Xin
    Meng Zhu
    Tian-Ze Lu
    Hao Liu
    Zheng Xu
    Peng Yu
    You-Cai Zhao
    Ming-Hao Li
    Zhi-Kai Hu
    Yan Zhao
    Bing Zhong
    Xiao Xu
    Liu-Hua Zhou
    Lu-Wei Xu
    Jian-Ping Wu
    Wen-Cheng Li
    Jia-Geng Zhu
    Rui-Peng Jia
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 1291 - 1299